Comparison of study designs, objectives and results of Phase I trials with cytotoxic versus non-cytotoxic anticancer agents | Allucent

Home  /  Resources  /  Poster  /  Comparison of study designs, objectives and results of Phase I trials with cytotoxic versus non-cytotoxic anticancer agents

Comparison of study designs, objectives and results of Phase I trials with cytotoxic versus non-cytotoxic anticancer agents

Comparison of study designs, objectives and results of Phase I trials with cytotoxic versus non-cytotoxic anticancer agents

Cytotoxic anticancer agents are designed to kill tumor cells by interfering with cell division mechanisms. In contrast, non-cytotoxic anticancer agents intend to inhibit cancer growth by targeting specific proteins or signaling pathways or by activating the immune system. We investigated whether these different modes of action are reflected in study designs, objectives and results of Phase I studies.

DOWNLOAD RESOURCE

Request a Proposal

Featured Content

Understanding ICH E11A Key Features of the Pediatric Extrapolation Guideline and Implications for Sponsors

Blog

ICH E11A: Key Features and Implications of the Pediatric Extrapolation Guideline

Read More

The Expansion of Cell & Gene Therapies into Autoimmune Disease 

Infographic

Shifting Frontiers: The Expansion of Cell & Gene Therapies into Autoimmune Disease 

Read More
Rare Disease Clinical Trials: Challenges, Strategies, and Solutions for Success

Blog

Rare Disease Clinical Trials: Challenges, Strategies, and Solutions for Success

Read More

View All Resources

Partner With the A-Team

Let us know how we can help you bring new therapies to light. Get in touch to get started.

Schedule a Consultation

Join the A-Team

Want to help small and mid-sized biotech companies change the therapeutic landscape?

View Open Jobs

Subscribe to our monthly newsletter